Question · asked by 1 review
Azithromycin vs doxycycline: Participant‐assessed improvement in rosacea severity
- Population
- Participants with rosacea
- Intervention
- Azithromycin
- Comparison
- doxycycline
- Outcome
- Participant‐assessed improvement in rosacea severity
It is very uncertain whether azithromycin changes participant‐assessed improvement in rosacea severity compared with doxycycline 100 mg (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Azithromycin vs doxycycline 100 mg Participant‐assessed improvement in rosacea severity · Participants with rosacea It is very uncertain whether azithromycin changes participant‐assessed improvement in rosacea severity compared with doxycycline 100 mg (very low certainty). Interventions for rosacea (2015) · Cochrane Headline outcomes only | RR 0.98 [0.77, 1.25] | 1 study · 67 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for rosacea 2015 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.